Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

Marius Pharmaceuticals has expanded its global footprint with Health Canada’s approval of KYZATREX® (testosterone undecanoate) CIII capsules

Marius Pharmaceuticals, Inc. a patient-centric healthcare company committed to advancing innovative therapies for testosterone deficiency, announced that Health Canada has approved KYZATREX® (testosterone undecanoate) CIII capsules. KYZATREX is a...

The BioTech Breakthrough Award has been granted to Asahi Kasei for the Planova™ FG1 Filter

(PES) membrane that achieves both high permeability and robust virus retention, advancing efficiency and safety in biopharmaceutical manufacturing. FG1 builds on the legacy of the Planova™ series — the world’s first virus removal filter, introduced...

Odyssey Therapeutics Welcomes Dennis Dean, Ph.D., as EVP, Non-Clinical Development

Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that precisely target disease pathology,...

HanchorBio Unveils Compelling New Data at SITC 2025 Highlighting the Best-in-Class Potential of HCB101 in Advanced Cancers

(TPEx: 7827) is a global biotechnology company specializing in immuno-oncology. It is led by an experienced team of pharmaceutical industry veterans with a proven track record in biologics discovery and international development, aiming to rewrite...

Gilead’s Livdelzi® Shows Sustained Efficacy in PBC, Reducing ALP, Relieving Itch, and Potentially Slowing Disease Progression

Gilead remains devoted to a future without liver disease. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a...

PRM Pharma Launches HemiClor® 12.5 mg, the First FDA-Approved Low-Dose Chlorthalidone Tablet for Hypertension

pharmacologic classes, including chlorthalidone. About PRM Pharma, LLC PRM Pharma, LLC is a privately held specialty pharmaceutical company focused on developing low-dose therapies that align with clinical practice guidelines and advance patient...

Leukogene Therapeutics’ M2T-CD33 (LTI-214) has received Orphan Drug Designation from the U.S. FDA for the treatment of Acute Myeloid Leukemia

Leukogene Therapeutics Inc. (LTI), a biopharmaceutical company developing next-generation immunotherapies for hematologic and other malignancies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation...

Data on BIMZELX® (bimekizumab-bkzx) in Hidradenitis Suppurativa Showed Sustained Improvements in Pain and Draining Tunnel Resolution for Three Years

UCB, a global biopharmaceutical company, announced three-year data from the BE HEARD trials for BIMZELX® (bimekizumab-bkzx) in moderate-to-severe hidradenitis suppurativa (HS). BIMZELX, the first and only medicine approved to selectively inhibit...

Phase 2 Data of GC Biopharma's Recombinant Anthrax Vaccine, BARYTHRAX, Demonstrates Safety and Immunogenicity, Published in 'Vaccine

GC Biopharma, a leading global pharmaceutical company based in South Korea, announced that the Phase 2 clinical trial results for its anthrax vaccine 'BARYTHRAX inj. (GC1109)' have been published in the international journal Vaccine. BARYTHRAX is...

Samsung Epis Holdings, Newly Established, to Drive Growth for Samsung Bioepis and Its New Subsidiary

have more opportunities to explore next-generation growth drivers.” As an investment holdings company dedicated to biopharmaceuticals and biotechnology, Samsung Epis Holdings will optimize business strategies for its subsidiaries and maximize...

Starting January 2026, Samsung Bioepis will commercialize BYOOVIZ® (ranibizumab) in Europe

Eylea that also covers OPUVIZ in Europe. About Samsung Bioepis Co., Ltd. Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product...

During FII Week in Riyadh, Rubedo Life Sciences and SVAX announce a strategic partnership

longevity science, and life sciences, with expertise in drug development and commercialization from both large pharmaceutical and leading biotechnology companies. The company is headquartered in Mountain View, CA, USA, and has offices in Milan,...

Baird Medical’s MWA system has achieved successful Medicare reimbursement at a prominent New York practice

through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance...

Prestigious Journal of Hematology & Oncology Accepts HanchorBio’s Novel CD47-SIRPα Therapeutic, HCB101, for Publication

(7827.TPEx), a global biotechnology company specializing in immuno-oncology, is led by an experienced team of pharmaceutical industry veterans with a proven track record of success in biologics discovery and international development, aiming to...

Mexico’s First Pharmaceutical Company, IFA Celtics, Deploys ForgeStop's NFC Anti-Counterfeit Tech

IFA Celtics, a leading Mexican pharmaceutical manufacturer, has partnered with ForgeStop Technology Corp, a U.S. connected product technology company, to launch NFC-enabled smart packaging that allows instant verification of medicines by...

Alcami to expand lab services at Durham, NC facility to meet rising biologics demand

investment reinforces Alcami's commitment to delivering comprehensive, integrated solutions that support the pharmaceutical and biotech industries from development to delivery. The 20,000-square-foot expansion, which began in Q4 2025 and is...

ADARx doses first patient in Phase 3 STOP-HAE trial; ADX-324 receives orphan drug designation for hereditary angioedema

ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA therapeutics, today announced that the first patient has been dosed in its Phase 3 STOP-HAE clinical trial evaluating ADX-324 in...

To drive global expansion of digital chemistry and discovery, Chemify raises over $50 million in an oversubscribed Series B round

globally, building a network of digital chemistry hubs and delivering on-demand molecule design and manufacturing to pharmaceutical, biotech and materials-science partners everywhere. Chemify plans to open a Silicon Valley facility led by Chief...

Mayo Clinic researchers have developed a first-in-kind, fully humanized 3D bioprinted human skin model using CollPlant's rhCollagen-based BioInk

innovative alternative to animal testing for preclinical research, with broad potential applications in cosmetic and pharmaceutical testing, disease modeling, and drug development. The novel model specifically consists of CollPlant's...

FDA Approves ZOLL’s Zenix Monitor/Defibrillator, Elevating Asahi Kasei’s Critical Care Solutions

Asahi Kasei, a global provider of healthcare technology and pharmaceutical solutions, has advanced its suite of critical care products through premarket approval by the U.S. Food and Drug Administration (FDA) for ZOLL’s Zenix®...